Abstract
9-Nitrocamptothecin (9-NC) is an efficient antitumor reagent with poor drug-to-lipid entrapment (1:72) in the conventional liposomes formulation. In order to improve the encapsulation and therapeutic efficacy, PEGylated cholesterol (Chol-PEG) was introduced into the 9-NC loaded liposomes formulation by pH gradient encapsulation method. Comparing with conventional composition, 9-NC/lipid molar ratio was increased from 1:72 up to 1:6 in the Chol-PEG based liposomes with uniform size distribution (~120 nm). PEGylated formulation showed obvious lower IC50 value than 9-NC solution (from > 50μmol/L to 5.5 μmol/L on breast cancer 4T1 cells, while from > 50μmol/L to 25.4 μmol/L on hepatoma HepG2 cells) in cytotoxicity measurement. The safety of PEGylated 9-NC liposomes formulation was also illustrated in ex vivo hemolysis test. The enhanced tumor inhibition efficiency of PEGylated 9-NC liposomes was confirmed from tumor-bearing BALB/c mice model using same dosage of 9-NC solution as control (from 28.6% to 70.1% in tumor inhibition). These results suggest that this Chol-PEG based liposome formulation may serve as a promising nanoscale platform for 9-NC controlled delivery.
Keywords: pH-gradient, 9-nitrocamptothecin, PEGylated in vitro, in vivo, cholesterol, liposomes.
Pharmaceutical Nanotechnology
Title:pH-Gradient Incorporation of 9-Nitrocamptothecin in PEGylated Liposomes: Formulation Properties and Efficacy In Vitro and In Vivo
Volume: 1 Issue: 2
Author(s): Shuang Chang, Li Xie, Hong Ding, Yu Nie, Yao Wu, Bin He and Zhongwei Gu
Affiliation:
Keywords: pH-gradient, 9-nitrocamptothecin, PEGylated in vitro, in vivo, cholesterol, liposomes.
Abstract: 9-Nitrocamptothecin (9-NC) is an efficient antitumor reagent with poor drug-to-lipid entrapment (1:72) in the conventional liposomes formulation. In order to improve the encapsulation and therapeutic efficacy, PEGylated cholesterol (Chol-PEG) was introduced into the 9-NC loaded liposomes formulation by pH gradient encapsulation method. Comparing with conventional composition, 9-NC/lipid molar ratio was increased from 1:72 up to 1:6 in the Chol-PEG based liposomes with uniform size distribution (~120 nm). PEGylated formulation showed obvious lower IC50 value than 9-NC solution (from > 50μmol/L to 5.5 μmol/L on breast cancer 4T1 cells, while from > 50μmol/L to 25.4 μmol/L on hepatoma HepG2 cells) in cytotoxicity measurement. The safety of PEGylated 9-NC liposomes formulation was also illustrated in ex vivo hemolysis test. The enhanced tumor inhibition efficiency of PEGylated 9-NC liposomes was confirmed from tumor-bearing BALB/c mice model using same dosage of 9-NC solution as control (from 28.6% to 70.1% in tumor inhibition). These results suggest that this Chol-PEG based liposome formulation may serve as a promising nanoscale platform for 9-NC controlled delivery.
Export Options
About this article
Cite this article as:
Chang Shuang, Xie Li, Ding Hong, Nie Yu, Wu Yao, He Bin and Gu Zhongwei, pH-Gradient Incorporation of 9-Nitrocamptothecin in PEGylated Liposomes: Formulation Properties and Efficacy In Vitro and In Vivo , Pharmaceutical Nanotechnology 2013; 1 (2) . https://dx.doi.org/10.2174/2211738511301020007
DOI https://dx.doi.org/10.2174/2211738511301020007 |
Print ISSN 2211-7385 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-7393 |
Call for Papers in Thematic Issues
Polymeric nanocarriers in drug delivery
Polymeric nanocarriers play a crucial role in drug delivery due to their versatility, and unique properties for targeting and modifying drug release. Their ability to enhance therapeutic outcomes, reduce side effects, and enable the delivery of drugs in a more targeted and controlled manner made them popular in the last ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Update on the Development of microRNA and siRNA Molecules as Regulators of Cell Physiology
Recent Patents on DNA & Gene Sequences Non-Photoinduced Biological Properties of Verteporfin
Current Medicinal Chemistry Synthesis, In Vitro Anticancer, Anti-Inflammatory and DNA Binding Activity of Thiazolidinedione Derivatives
Anti-Cancer Agents in Medicinal Chemistry A Review on The Role of VEGF in Tamoxifen Resistance
Anti-Cancer Agents in Medicinal Chemistry Vitamin E–TPGS Stabilized Self-Assembled Tripeptide Nanostructures for Drug Delivery
Current Topics in Medicinal Chemistry Intercellular Crosstalk Via Extracellular Vesicles in Tumor Milieu as Emerging Therapies for Cancer Progression
Current Pharmaceutical Design Biological Activities of QIAPI 1 as a Melanin Precursor and Its Therapeutic Effects in Wistar Rats Exposed to Arsenic Poisoning
Central Nervous System Agents in Medicinal Chemistry Endometriosis and Gynecological Cancer
Current Women`s Health Reviews Redox mechanisms in pathological angiogenesis in the retina: roles for NADPH oxidase
Current Pharmaceutical Design Synthesis and Anti-Breast Cancer Activity of Tetrasubstituted Pyrrole Derivatives
Letters in Drug Design & Discovery Site Targeted Press Coated Delivery of Methylprednisolone Using Eudragit RS 100 and Chitosan for Treatment of Colitis
Recent Patents on Anti-Infective Drug Discovery Graphical Abstracts
Current Drug Delivery Applications of Peptide Mimetics in Cancer
Current Medicinal Chemistry Editorial (Thematic Issue: Antitarget Therapies: New Frontiers in the Treatment of Cancer)
Anti-Cancer Agents in Medicinal Chemistry Targeting Schistosome Histone Modifying Enzymes for Drug Development
Current Pharmaceutical Design Transcriptome Analysis of MDA-MB-231 Cells Treated with Fumosorinone Isolated from Insect Pathogenic Fungi
Anti-Cancer Agents in Medicinal Chemistry Microarrays and Colon Cancer in the Road for Translational Medicine
Current Bioinformatics Bombesin-like Peptides: Candidates as Diagnostic and Therapeutic Tools
Current Pharmaceutical Design Interaction of Mesalasine (5-ASA) with Translational Initiation Factors eIF4 Partially Explains 5-ASA Anti-Inflammatory and Anti-Neoplastic Activities
Medicinal Chemistry The Role of PET/CT and SPECT/CT in Oncology Drug Development
Current Molecular Imaging (Discontinued)